In Brief: Heartport
This article was originally published in The Gray Sheet
Executive Summary
Heartport: Acquires Utah Biomedical Test Laboratory, which the Redwood City, California company plans to use as the principal U.S. training center for its Port-Access minimally invasive cardiac surgery. Training is scheduled to begin this quarter at the 50,000-square-foot surgical laboratory. The facility will enable Heartport to "centralize and accelerate its U.S. training activities" and to "substantially accelerate and broaden its research and development activities," the firm says. On Oct. 7, Heartport received FDA clearance for the EndoCPB catheter system to perform Port-Access coronary artery bypass grafting and other cardiac surgeries. Heartport plans to launch the system by mid-1997 following physician training ("The Gray Sheet" Oct. 14, I&W-1)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.